Pharmaceuticals

Psoriasis Market Size and Growth Forecast for Businesses 2025–2029

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Growth Projections For The Psoriasis Market Size During 2025–2029?

The psoriasis market size has seen significant growth in recent years. It is anticipated to expand from $26.45 billion in 2024 to $28.93 billion in 2025, achieving a compound annual growth rate (CAGR) of 9.4%. This historical growth can be attributed to factors such as epidemiology, enhanced patient awareness and education, and improved healthcare infrastructure and access.

The psoriasis market is anticipated to exhibit significant expansion in the coming years. It is projected to achieve a size of $40.93 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 9.1%. The expected growth over this period can be ascribed to factors such as regulatory clearances, evolving patient preferences, an aging demographic, heightened public awareness, and the introduction of new therapeutic options. Prominent trends within the forecast timeframe include continuous advancements in research and development, the increasing prevalence of biologics and targeted therapies, the development of oral small molecule treatments, the adoption of personalized medicine, the growth of telemedicine and digital health, an emphasis on patient-centric care, the availability of biosimilars, and the incorporation of artificial intelligence and machine learning.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2414&type=smp

Which Drivers Are Shaping The Psoriasis Industry’s Market Share?

The increasing prevalence of individuals with psoriasis is a primary factor driving the Psoriasis market. This condition stems from issues related to the immune system, genetics, and environmental elements. The rise in psoriasis patients observed over the past few years can be chiefly attributed to shifts in climate, heightened stress, and unhealthy lifestyles. As per the World Psoriasis Day consortium, 125 million people globally – 2 to 3% of the total population have psoriasis. Consequently, this growing prevalence of psoriasis patients is anticipated to propel the growth of the psoriasis over forecast period.

What Are The Emerging Segments Gaining Attention In The Psoriasis Market?

The psoriasis market covered in this report is segmented –

1) By Drug class: Interleukin Inhibitors, Corticosteroids, Anti-Inflammatory, Tumor Necrosis Factor Inhibitor

2) By Drug Types: Small molecules, Biologics

3) By Disease Indication: Plaque Psoriasis, Nail Psoriasis, Guttate Psoriasis, Pustular Psoriasis, Erythrodermic Psoriasis

4) By Route Of Administration: Oral, Tropical, Injectable

5) By Distribution Channel: Hospitals, Retail Pharmacies, E-Commerce

Subsegments:

1) By Interleukin Inhibitors: IL-12/23 Inhibitors (Ustekinumab), IL-17 Inhibitors (Secukinumab, Ixekizumab)

2) By Corticosteroids: Topical Corticosteroids (Hydrocortisone, Betamethasone), Systemic Corticosteroids (Prednisone)

3) By Anti-Inflammatory: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Biologic Anti-Inflammatory Agents (Apremilast)

4) By Tumor Necrosis Factor (TNF) Inhibitors: Adalimumab (Humira), Etanercept (Enbrel), Infliximab (Remicade)

What Trends Are Expected To Drive The Psoriasis Market?

In the psoriasis market, combination therapy stands as an evolving trend. This treatment strategy involves the simultaneous application of two distinct psoriasis treatments. When two drugs possessing different mechanisms of action are combined, this approach, known as combination therapy, achieves a greater effect than that derived from monotherapy, which relies on a single drug. Studies indicate that combination therapy alleviates psoriasis symptoms more effectively than a single treatment and is associated with fewer side effects. An example of combination therapy for managing active psoriatic arthritis (PsA) is the combination of taltz (ixekizumab) with methotrexate, developed by Eli Lilly and Company.

Who Are The Primary Competitors In The Global Psoriasis Market?

Major companies operating in the psoriasis market include AbbVie Inc., Pfizer Inc., Novartis AG, Eli Lilly and Company, Celgene Corporation, Johnson & Johnson, Amgen Inc., Boehringer Ingelheim GmbH, Merck & Co. Inc., Janssen Biotech Inc., Takeda Pharmaceutical Company Limited, Stiefel Laboratories Inc., AstraZeneca Inc., Union Chimique Belge SA, Sun Pharmaceutical Industries Ltd., Forward Pharma AS, Almirall SA, Bausch Health Companies Inc., Biogen Inc., Biocon Biopharmaceuticals Pvt. Ltd., Celltrion Inc., Dr.Reddy’s Laboratories Inc., Arcutis Biotherapeutics Inc., Bayer AG, Bristol Myers Squibb Co., Dermira Inc., Galderma SA, GlaxoSmithKline Plc, Incyte Pharmaceuticals Corp., LEO Pharmacy

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/psoriasis-drugs-global-market-report

Which Global Regions Are Influencing The Competitive Landscape Of The Psoriasis Market?

North America was the largest region in the psoriasis market in 2024. Middle East is expected to be the fastest-growing region in the psoriasis market during the forecast period. The regions covered in the psoriasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Psoriasis Market Report:

https://www.thebusinessresearchcompany.com/customise?id=2414&type=smp

Browse Through More Reports Similar to the Global Psoriasis Market 2025, By The Business Research Company

Dermatology Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report

Pharmaceutical Drugs And Biologics Logistics Market 2025

https://www.thebusinessresearchcompany.com/report/pharmaceutical-drugs-and-biologics-logistics-market

Analgesics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/analgesics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795